Cho Young Ae, Kong Sun-Young, Shin Aesun, Lee Jeonghee, Lee Eun Kyung, Lee You Jin, Kim Jeongseon
Division of Cancer Epidemiology and Prevention, Molecular Epidemiology Branch, Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si 410-769, Gyeonggi-do, Korea.
BMC Cancer. 2014 Nov 24;14:873. doi: 10.1186/1471-2407-14-873.
A remarkable increase in the number of thyroid cancer cases has been reported in recent years; however, the markers to predict high-risk groups have not been fully established.
We conducted a case-control study (257 cases and 257 controls) that was nested in the Cancer Screenee Cohort Study between August 2002 and December 2010; the mean follow-up time for this study was 3.1 ± 2.2 years. The levels of total triiodothyronine (TT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), thyroglobulin (Tg), anti-thyroperoxidase antibody (TPOAb), and anti-thyroglobulin antibody (TgAb) were measured using samples with pre-diagnostic status. Logistic regression models were used to examine the association between thyroid function/autoimmunity and thyroid cancer risk.
When the markers were categorized by the tertile distributions of the control group, the highest tertile of FT4 (OR = 1.73, 95% CI = 1.11 - 2.69) and the middle tertile of TSH (OR = 1.77, 95% CI = 1.14 - 2.74) were associated with an increased risk of thyroid cancer by multivariate analyses. In addition, an elevated risk for thyroid cancer was found in subjects with TPOAb levels above 30 IU/mL (OR = 8.47, 95% CI = 5.39 - 13.33 for 30-60 IU/mL and OR = 4.48, 95% CI = 2.59 - 7.76 for ≥60 IU/mL). Stratified analyses indicated that some of these associations differed by sex, BMI, smoking status, and the duration of follow-up.
This study demonstrated that the levels of biomarkers of thyroid function/autoimmunity, particularly the presence of TPOAb, might be used as diagnostic markers for predicting thyroid cancer risk. Our findings suggest that careful monitoring of thyroid biomarkers may be helpful for identifying Korean populations at high-risk for thyroid cancer.
近年来,甲状腺癌病例数显著增加;然而,预测高危人群的标志物尚未完全确立。
我们进行了一项病例对照研究(257例病例和257例对照),该研究嵌套于2002年8月至2010年12月的癌症筛查队列研究中;本研究的平均随访时间为3.1±2.2年。使用诊断前状态的样本测量总三碘甲状腺原氨酸(TT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、甲状腺球蛋白(Tg)、抗甲状腺过氧化物酶抗体(TPOAb)和抗甲状腺球蛋白抗体(TgAb)的水平。采用逻辑回归模型检验甲状腺功能/自身免疫与甲状腺癌风险之间的关联。
当根据对照组的三分位数分布对标志物进行分类时,多因素分析显示,FT4的最高三分位数(OR = 1.73,95%CI = 1.11 - 2.69)和TSH的中间三分位数(OR = 1.77,95%CI = 1.14 - 2.74)与甲状腺癌风险增加相关。此外,TPOAb水平高于30 IU/mL的受试者患甲状腺癌的风险升高(30 - 60 IU/mL时,OR = 8.47,95%CI = 5.39 - 13.33;≥60 IU/mL时,OR = 4.48,95%CI = 2.59 - 7.76)。分层分析表明,其中一些关联因性别、体重指数、吸烟状况和随访时间而异。
本研究表明,甲状腺功能/自身免疫的生物标志物水平,尤其是TPOAb的存在,可能用作预测甲状腺癌风险的诊断标志物。我们的研究结果表明,仔细监测甲状腺生物标志物可能有助于识别韩国甲状腺癌高危人群。